BIOCDX (HORIZON 2020)
January 2017, Surfix BV is proud to participate in the BIOCDx program first launched in January 2017 and funded by the ‘European Union Funding for Research & Innovation’. Within the project, partners from four different countries – Greece, Germany, Switzerland and The Netherlands – work on the development of a miniaturized, ultra-sensitive and reliable Point-of-Care (PoC) device with a disposable microfluidic cartridge for the monitoring of cancer biomarkers. The developed PoC device will support the detection of primary tumors and metastases focusing on breast cancer, hormone-independent prostate cancer and melanoma.
To this end the consortium gathered expertise from the photonic, nano-biochemical, micro-fluidic and reader/packaging platform to develop a portable, desktop PoC device. Within the BIOCDx project Surfix BV will supply the nanocoatings necessary to immobilize the different biomarkerson the surface.
If you want to know more about Surfix and its technologies, visit our website.